What Does the NIH Sister Study Mean for My Breast Cancer Risk?

ER-negative breast cancer is less common and generally more aggressive than ER-positive disease, and it has few known risk factors. A new NIH analysis of the Sister Study, published in the Journal of Clinical Oncology, adds a candidate: women with the highest blood levels of PFOA and PFOS, measured years before breast cancer diagnosis, went on to develop ER-negative cancer more often.

What the Sister Study measured, and what it found

In the Sister Study, blood drawn at enrollment was stored. For this analysis, researchers measured 17 PFAS in samples from 1,609 women who later developed breast cancer, 324 of them ER-negative. Collecting blood before diagnosis reduces the chance that cancer or its treatment altered the levels, a problem that has muddied studies drawing blood after diagnosis. The models also accounted for other risk factors and for correlated PFAS in each woman's blood.

Comparing the top quarter of exposure with the bottom, PFOA was linked to about a two-thirds higher rate of ER-negative breast cancer, and PFOS to a rate nearly twice as high. Neither chemical was clearly linked to breast cancer overall or to the more common ER-positive type. Those results can coexist because ER-negative disease is less common, so a subtype association may be less apparent in the overall result.

This was an observational study, so it cannot establish cause and effect. With 324 ER-negative cases, the estimates are fairly imprecise. For PFOA, evidence for a rising rate across exposure quarters was inconclusive, while PFOS showed a clearer trend. The results are relative comparisons between exposure groups, and the study doesn't give you a personal lifetime probability. The authors suggest PFAS might act through routes other than hormones, such as changes in gene activity or immune function, but they didn't test that idea.

The family-history design cuts both ways. It limits how confidently the findings apply to women without an affected sister. If you do have a sister with breast cancer, though, you share that characteristic with the women who were studied.

PFOA has the more consistent evidence

What gives PFOA more weight is that the authors also updated a pooled analysis of seven studies that measured PFAS in blood before diagnosis, and the PFOA link to ER-negative cancer held up there, while the PFOS estimate stayed compatible with no association. Earlier prospective work points the same way. In a large US cancer-screening trial and in France's E3N cohort, PFOA showed signals for receptor-negative tumors, though risk didn't rise consistently with dose. PFOS has been less consistent: in that US trial it was tied to ER-positive tumors and showed no clear association with receptor-negative ones.

Lowering what's in your blood starts with water

PFOA and PFOS leave the body slowly, and no medical treatment is approved specifically to remove PFAS, so cutting ongoing intake is the main lever. When two public water systems in Ohio and West Virginia added granular activated carbon filtration, residents' blood PFOA fell during follow-up, and a larger surveillance program in Italy's Veneto region saw a similar decline after contaminated water was cleaned up. A large decline can take years; PFOA's estimated half-life in these studies was a little over two years. The Veneto study also tracked PFOS, but ongoing exposure complicated estimates of how quickly it leaves the body.

Those results come from utility-scale treatment, so a home filter may not match them. EPA's guidance is to choose a filter certified specifically for PFAS reduction under NSF/ANSI standard 53 or 58 and to replace it as the maker directs, since spent carbon lets contaminants back through. EPA also notes that certification by itself doesn't prove a filter brings water down to the federal limit.

This matters most if your water is a known source, such as a public system that has reported PFAS or a private well with confirmed contamination. If that's your situation, effective filtration lowers your exposure, and the Sister Study adds a possible link to an aggressive cancer to the reasons for doing it.

Where blood testing and screening fit

A PFAS blood test measures exposure. The Agency for Toxic Substances and Disease Registry says it can't predict whether you'll get sick or show that PFAS caused an illness you already have, and it suggests basing the decision on your exposure history and whether a result would change what you do. If you suspect contaminated water, a high blood level may support investigating exposure, but it cannot identify the source, and the clinical value and best timing of repeat testing are unknown. National Academies guidance for moderately elevated levels calls for reducing exposure while keeping breast screening within usual standards of care.

Breast screening decisions still rest on age and established risk factors, family history among them, so a sister with breast cancer already counts in that assessment. Neither ATSDR nor National Academies guidance sets a PFAS level that triggers extra breast imaging, and this study doesn't supply evidence that would justify one.

What the next studies need to show

The Sister Study gives you a firmer reason to treat an identifiable PFOA exposure as worth fixing, and effective filtration of contaminated water can bring the level down. Whether that lower level means less ER-negative breast cancer remains unknown. Answering it would take replication in women without a family history, with enough ER-negative cases to give precise estimates, blood measured more than once, and eventually evidence that women whose exposure fell went on to develop this cancer less often.